AC Immune Q3 2019 Financial Results and Business Update
CHF 32 Million in Milestone Revenues
Multiple Upcoming Catalysts
Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline
AC Immune SA, a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today provided a business and clinical update and reported its consolidated financial results for the third quarter of 2019.